Velan Capital Investment Management LP Invests $2.09 Million in ADMA Biologics Inc $ADMA

Velan Capital Investment Management LP acquired a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 250,000 shares of the biotechnology company’s stock, valued at approximately $2,092,000. ADMA Biologics comprises about 1.3% of Velan Capital Investment Management LP’s investment portfolio, making the stock its 18th largest holding. Velan Capital Investment Management LP owned 0.11% of ADMA Biologics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ADMA. Royal Bank of Canada boosted its stake in shares of ADMA Biologics by 448.8% during the first quarter. Royal Bank of Canada now owns 929,326 shares of the biotechnology company’s stock valued at $8,373,000 after acquiring an additional 759,984 shares during the last quarter. Bank of America Corp DE raised its stake in ADMA Biologics by 107.5% in the 1st quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company’s stock valued at $36,019,000 after purchasing an additional 2,071,338 shares during the last quarter. Louisiana State Employees Retirement System purchased a new position in ADMA Biologics in the 1st quarter valued at about $951,000. BNP Paribas Financial Markets lifted its holdings in ADMA Biologics by 2,188.4% in the 4th quarter. BNP Paribas Financial Markets now owns 1,141,106 shares of the biotechnology company’s stock valued at $20,814,000 after purchasing an additional 1,091,241 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd boosted its stake in shares of ADMA Biologics by 1,508.1% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 1,075,422 shares of the biotechnology company’s stock worth $9,690,000 after purchasing an additional 1,008,548 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $9.33 on Wednesday. ADMA Biologics Inc has a one year low of $7.21 and a one year high of $20.46. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.81 and a current ratio of 6.97. The company has a 50 day moving average price of $9.10 and a 200 day moving average price of $10.40. The firm has a market capitalization of $2.09 billion, a price-to-earnings ratio of 13.33 and a beta of 0.78.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The company had revenue of $124.39 million for the quarter, compared to analyst estimates of $125.34 million. During the same quarter last year, the business earned $0.14 EPS. ADMA Biologics’s revenue for the quarter was up 2.0% on a year-over-year basis. Sell-side analysts anticipate that ADMA Biologics Inc will post 0.78 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on ADMA shares. Canaccord Genuity Group lowered their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Mizuho decreased their target price on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Zacks Research cut shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 4th. Finally, Raymond James Financial assumed coverage on ADMA Biologics in a report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 price target for the company. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $18.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.